ASH 2018 and Multiple Myeloma View overview page

2:45
Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn
1:28
MM has a bright future: highlights from ASH
Mark Bustoros
3:59
Promising combination of ixazomib, lenalidomide & dex in high-risk smoldering myeloma
Mark Bustoros
1:23
Melflufen and dex with bortezomib/daratumumab for myeloma: OP-104 study
Enrique Ocio
1:51
Predicting IMiD sensitivity in myeloma
Rafael Fonseca
0:57
High economic burden for progressive multiple myeloma: considering costs
Rafael Fonseca
3:11
Isatuximab plus VRd for newly diagnosed transplant-ineligible myeloma
Enrique Ocio
1:06
High treatment attrition in newly diagnosed multiple myeloma patients
Rafael Fonseca
1:59
Multiple myeloma musings: highlights from 2018 data
Joshua Richter
1:04
Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
Joshua Richter
1:57
Pivotal STORM study: selinexor for penta-refractory multiple myeloma
Joshua Richter
04:22
Mohamad Mohty’s myeloma highlights from ASH 2018
Mohamad Mohty
04:11
An exciting era for CAR T-cell therapy
Mohamad Mohty
1:12
Hot topic: Geriatric Assessment in Hematology (GAH) scale
Raúl Córdoba
3:27
Understanding myeloma disease dissemination: are CTCs responsible?
Bruno Paiva
2:12
A step towards next-generation immune monitoring in multiple myeloma?
Bruno Paiva
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals